Improving our understanding of the genetics of neuroblastoma
Understanding neuroblastoma heterogeneity: genetic studies of circulating neuroblastoma tumour cells
Developing new treatments for high-risk neuroblastoma
Pre-clinical efficacy and biomarker studies of ALK, MAPK and MDM2-p53 inhibitor combinations in neuroblastoma
Developing better and safer medicines for children with leukaemia
Screening for novel drug combinations in childhood B-cell acute lymphoblastic leukaemia